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SUMMARY
As a group, we met to discuss the current challenges for creating meaningful patient-specific in vitro models to study brain disorders.
Although the convergence of findings between laboratories and patient cohorts provided us confidence and optimism that hiPSC-based
platforms will inform future drug discovery efforts, a number of critical technical challenges remain. This opinion piece outlines our col-
lective views on the current state of hiPSC-based disease modeling and discusses what we see to be the critical objectives that must be
addressed collectively as a field.
Just 10 years since the development of human induced
pluripotent stem cell (hiPSC) technology (Takahashi
et al., 2007), the use of these cells to model brain disorders
and obtain disease-relevant information is becoming a
tangible reality. Not only are we now able to better detect
relevant genetic changes in a patient’s cells using high-
throughput genome sequencing technology but also we
can establish a direct phenotypic correlation between
genetic mutations and an aberrant neuronal phenotype
or developmental trajectory. The latest improvements in
generating relevant neural cell types by either differentia-
tion of hiPSC lines or by direct conversion of somatic cells
(e.g., fibroblasts) now allow researchers to make cells from
different areas of the central nervous system (CNS) and pe-
ripheral nervous system (PNS) and probe effects on the cell
type where disease manifests. This represents a significant
improvement of previous experimental tools, including
animal models and in vitro cultures of non-relevant cell
lines (such as 293T or HeLa cells), which recapitulate only
some of the specific traits of human disease (Eglen and Re-
isine, 2011; Pouton and Haynes, 2005), with the potential
to reverse the current trend of huge investments by the
pharmaceutical industry yielding few therapeutic com-
pounds entering the market (Mullard, 2015; Scannell
et al., 2012).
In April 2015, a group of stem cell researchers, neurosci-
entists, genomic and computational biologists, clinicians,
and industry partners met for 4 days at the Banbury Cen-
ter at Cold Spring Harbor, New York, to discuss the current
challenges for creating meaningful patient-specific in vitro
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models to study brain disorders (Figures 1 and 2). This
opinion piece outlines the current state of the field and
discusses the main challenges that should drive future
research initiatives.
Defining Cell States
The initial discussion at the Banburymeeting addressed the
basic properties of stem cells and the increasing apprecia-
tion of the heterogeneity of the pluripotent state. The
most basic definition of ‘‘pluripotency’’ is the ability of a
single cell to differentiate into cells from all three germ
layers; however, an improved understanding of the vari-
eties of stem cells and pluripotent states available will
broaden the types of cells used as sources for disease
modeling and potentially improve production of specific
cell types. While we now understand that a variety of
artificial stem cell states may be possible during the reprog-
ramming process (Benevento et al., 2014; Clancy et al.,
2014; Lee et al., 2014; Tonge et al., 2014), originally, two
distinct states of pluripotency were apparent: (1) a ‘‘naive’’
ground state, which was leukemia inhibitory factor
(LIF)-dependent, capable of generating both embryonic
and extra-embryonic cell lineages, and resembled the prop-
erties of mouse embryonic stem cells (mESCs); and (2) a
‘‘primed’’ state, which was FGF2-dependent, reminiscent
of ‘‘epiblast’’ identity, and resembled human embryonic
stem cells (hESCs) (reviewed by Stadtfeld and Hochedlin-
ger, 2010). In mice, it is well established that inhibition
of ERK1/ERK2 and GSK3b (2i/LIF) is necessary to maintain
the naive state (Marks et al., 2012; Ying et al., 2008); with-
drawal of 2i/LIF is sufficient to drift naive cells to the
primed state (Brons et al., 2007). Recently, several groups
have described culture conditions for maintaining trans-
gene-independent hESCs that share various properties
with mESCs (Chan et al., 2013; Gafni et al., 2013; Marinho
et al., 2015; Valamehr et al., 2014; Ware et al., 2014). Most
compellingly, Hanna and colleagues reported that 2i/LIF,
together with EGF, FGF2, JNKi, ROCKi, and p38I, not
only converted primed hESCs to the naive state but also
conferred competence to form cross-species chimeric
mouse embryos (Gafni et al., 2013).While culture ofmouse
cells in 2i/LIF can convert cells from the primed into the
naive ground state, this is not sufficient to convert primed
human cells into a naive state. A number of different proto-
cols have been published using a variety of cytokines and
inhibitors, with gene expression analyses used to charac-
terize the state of pluripotency. The transcriptome of naive
cells generated by some protocols resembled that of mouse
naive cells and cleavage human embryos (Takashima et al.,
2014; Theunissen et al., 2014), whereas the transcriptome
of naive cells produced by other protocols more closely
resembled that of primed cells (Brons et al., 2007; Chan
et al., 2013; Gafni et al., 2013; Valamehr et al., 2014;
Ware et al., 2014). Thus, no consensus on what constitutes
the naive human state has been reached, and it is possible
that different states of pluripotency exist in human cells.
Within this context, a number of presenters considered
the importance of carefully defining cell states, in partic-
ular the nature of pluripotency.
Rudolf Jaenisch, from the Whitehead Institute for
Biomedical Research, reported on iterative chemical
screening to evaluate alternative culture conditions
Figure 1. Current Challenges for Creating Meaningful Patient-Specific In Vitro Models to Study Brain Disorders
A critical limitation of the field at present is the inherent difficulty in accurately defining cell states, particularly concerning the temporal
and regional identity of pluripotent cells, neurons, and glial cells. A next step for hiPSC-based models of brain disorders will be building
neural complexity in vitro, incorporating cell types and 3D organization to achieve network- and circuit-level structures. As the level of
cellular complexity increases, new dimensions of modeling will emerge, and modeling neurological diseases that have a more complex
etiology will be accessible. An important caveat to hiPSC-based models is the possibility that epigenetic factors and somatic mosaicism
may contribute to neurological and neuropsychiatric disease, risk factors that may be difficult to capture in reprogramming or accurately
recapitulate in vitro differentiation. A critical next step, in order to enable the use of hiPSCs for drug discovery, will be improving the
scalability and reproducibility of in vitro differentiations and functional assays.
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for naive human pluripotency, ultimately yielding an
improved combination of five kinase inhibitors (5i/L/FA)
that induces and maintains OCT4 distal enhancer activity
when applied directly to conventional hESCs (Theunissen
et al., 2014). Using these optimized conditions, his group
demonstrated direct conversion of primed to naive ESCs
in the absence of transgenes and isolation of novel hESCs
from human blastocysts. They noted, however, that naive
hESCs showed upregulated XIST and evidence of X inacti-
vation, raising the possibility that X inactivation in naive
stem cells inmouse andhumanmay be different. Critically,
transplantation of GFP-positive human naive hESCs into
mouse blastocysts yielded no GFP-positive E10.5 embryos,
either by their original method (n = 860 embryos) or by
publishedmethods (Gafni et al., 2013) (n = 436+ embryos).
PCR for human mitochondria is a more sensitive assay,
identifying even the presence of 1/10,000 human cells,
but this also failed to detect mouse-human chimerism.
Although the generation of interspecies chimeras by injec-
tion of human ESCs into mouse morulae was proposed as a
stringent assay for naive human pluripotency (Gafni et al.,
2013), the assay may be too inefficient for use as a routine
functional assay. Instead, Jaenisch suggested that expres-
sion profiling is the best method to define naive versus
primed ESCs, noting that principal component analysis
(PCA) of gene expression from naive hESCs clusters close
to mESCs and far from primed hESCs.
Jun Wu, from the Izpisua Belmonte lab at the Salk Insti-
tute of Biological Studies, also spoke briefly of recent diffi-
culties in generating viable chimeras following injection
of naive human iPSCs tagged with a GFP reporter (hiPSC-
GFP). Fortuitously, these studies led to media formulations
that allowed his group to expand and propagate mouse
epiblast stem cell cells (mEpiSCs) from embryonic day
5.75 (E5.75) embryos. When cultured with both FGF2
andWNT inhibition (IWR1), in the absence of serum, these
mouse epiblast stem cells showed high cloning efficiency,
comparable to that observed in mESCs. Careful character-
ization revealed a surprising regional specification of these
cells (now termed rsEpiSCs); upon transplantation into
mouse embryos, although they could contribute to all
three germ layers, they could only incorporate into the pos-
terior of the embryo, but not the distal or anterior regions
(Wu et al., 2015). Similar culture conditions yielded human
Figure 2. Banbury Meeting Attendees
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rsPSCs, which also contributed to all three germ layers,
exclusively in the posterior region, of chimeric mouse em-
bryos (Wu et al., 2015). This is in sharp contrast to conven-
tional human PSCs, which failed to incorporate in E7.5
mouse epiblast; global genome-wide expression analysis
confirmed that these stem cell states have unique molecu-
lar signatures.
Ronald McKay, of the Lieber Institute for Brain Studies,
further considered molecular regulation of stem cell
identity. Sophisticated immunohistochemical analyses re-
vealed unexpected dynamics in the level of pluripotent
gene expression, which was high immediately following
passaging and declined between splitting and varied be-
tween colonies and cultures, relative to their location
within the colony (Chen et al., 2014). The transcriptional
identity of each stem cell line, however, was stable across
datasets and between laboratories, evidence that the dy-
namic variation between PSCs is defined by our individual
human genomes (Adamo et al., 2015). This transcriptional
identity not only is conserved in replicate cell lines derived
from the same genome but also is stable throughout differ-
entiation; the signature can be detected in post-mortem
brain tissue matched to individual stem cell lines. Such sig-
natures may provide a useful means to both classify and
assess risk within stratified patient populations without
requiring advance knowledge of the target neural cell
type(s).
NissimBenvenisty, fromHebrewUniversity of Jerusalem,
discussed epigenetic regulation of stem cells. By generating
parthogenetic hiPSCs from female teratomas that harbor
two sets of maternal chromosomes, his group was able to
identify novel imprinted genes, including many miRNAs
(Stelzer et al., 2011). Rather than observing decreased
expression in all paternally expressed genes in parthoge-
netic hiPSCs, he reported that about half of the known
paternally expressed genes were unexpectedly not down-
regulated. Two classes of imprinted genes were resolved:
the first was downregulated in all parthenogenetic cell
types and included classical imprinted genes such as
PEG10, whereas the second was not downregulated in
some or all examined parthenogenetic cell types and
showed overlapping imprinted and non-imprinted iso-
forms; this resulted from expression from two promoters,
only one of which was imprinted (Stelzer et al., 2015). In
this context, Benvenisty considered whether parthenoge-
netic hiPSCs could be used tomodel epigenetic human dis-
orders such as the neurological Prader-Willi Syndrome
(PWS), which results from maternal uniparental disomy
of chromosome 15. Characterization of the parthogenetic
PSCs and iPSCs from PWS patients revealed specific
maternal expression of the DLK1-DIO3 locus in chromo-
some 14. The data suggest that an imprinted gene can
work in trans, because the loss of expression of IPW, an
imprinted long noncoding RNA in the PWS region, is a
regulator of DLK1-DIO3 region. This supports a working
model that paternal chromosome 15 mutation in PWS
leads to loss of IPW and subsequent upregulation of
maternal genes (Stelzer et al., 2014).
From these talks arose a discussion of the various tools by
which one could define cell states. There was general agree-
ment that genome-wide transcription analysis, both of
populations or cells, and particularly at the single-cell
level to resolve heterogeneity, was highly informative.
Moreover, genetic and epigenetic editing, combined with
selective use of cell-line derivation methods, could be
tailored to the unique requirements for mechanistic
studies of any particular disorder. Finally, as one considers
modeling neurological and psychiatric diseases, it is critical
that the field as a whole establishes whether or not there is
an ideal starting somatic cell type, reprogramming meth-
odology, and/or pluripotency cell state from which to
initiate hiPSC-based diseasemodeling experiments of brain
disorders.
Building Complexity to Neuronal Development
In Vitro
From here, the focus of discussions turned toward novel
methods togeneratedefinedcell types and their application
toward a number of highly penetrant neurodevelopmental
and neurodegenerative disorders. There was consistent dis-
cussion of the critical need to build complexity into hiPSC-
based models of neuronal development, first, by more
efficiently differentiating and maturing pure populations
of neurons, astrocytes, and other neural cell types, and, sec-
ond, by allowing these populations to self-organize into
defined circuits and three-dimensional (3D) systems (orga-
noids) (Eiraku et al., 2008; Kadoshima et al., 2013; Mariani
et al., 2012). Earlier work had shown that organoids recapit-
ulate morphogen gradients, cell polarity, layer formation,
and other essential features of morphogenesis. Ultimately,
there is a need to return to the in vivo environment, and a
numberof researchers discussed earlywork in transplanting
human hiPSC neurons back into either fetal or adult
mouse brains (chimeras), in order to track connectivity
and systems-level functionality of these cells in vivo
(Muotri et al., 2005), on the basis of early evidence that
hESC-derived human neurons can cross-talk with mouse
neurons.
Oliver Bru¨stle, from the University of Bonn, reported on
several stable intermediate neural stem cell populations,
which reflect different stages of CNS development and
thus facilitate standardized generation of neurons and glia
from human pluripotent stem cells (for review, see Karus
et al., 2014). The latest addition to this assortment is radial
glia-like neural stem cells, which, in contrast to develop-
mentally earlier neural stem cell (NSC) populations, are
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endowedwith a stable regional identity and enable efficient
and more rapid oligodendroglial differentiation (Gorris
et al., 2015). Bru¨stle also gave an update on the StemCell-
Factory project, an automated platform for parallelized
industrial-scale cell reprogramming and neural differentia-
tion (http://www.stemcellfactory.de/). He discussed several
applications of PSC-derivedNSCs. First, he presented recent
comparisons of gamma secretase modulators, finding
that amyloid precursor protein (APP) processing in hiPSC
neurons is resistant to non-steroidal anti-inflammatory
drug (NSAID)-based gamma-secretasemodulation (Mertens
et al., 2013). This is in contrast to results fromtransgenic cell
lines and mouse models, indicating the need to validate
compound efficacy directly in the human cell type affected
by disease. Second, Bru¨stle developed an hiPSC-based
model of the polyglutamine disorder Machado-Joseph
disease (spinocerebellar ataxia type 3) to illustrate how the
earliest steps in protein aggregation can be modeled in
patient-derived cells (Koch et al., 2011). Aggregates of
ataxin-3 were observed specifically in hiPSC-derived neu-
rons, but not in primary patient fibroblasts, hiPSCs, or
hiPSC-derived glial cells. His group’s findings indicate that
pronounced neuronal intranuclear inclusions are specific
to neurons and help to explain the reason for neuron-spe-
cific degeneration in this disease. Finally, he also discussed
latest developments in studying in vivo integration and
connectivity phenotypes of transplanted iPSC-derivedneu-
rons with rabies-virus-based monosynaptic tracing and
light sheet microscopy of whole-brain preparations.
Allison Ebert, from the Medical College of Wisconsin,
described methods for generating astrocyte cultures of
improved purity from hiPSCs. In contrasting other recent
reports (Emdad et al., 2012; Krencik et al., 2011; Serio
et al., 2013), she noted the lengthy duration of existing pro-
tocols, which required months to differentiate and expand
astrocytes, and she reported on recent attempts to use
magnetic activated cell sorting (MACS)-based methods,
and even simple cellular passaging, to positively select
for astrocyte fate within weeks. Despite some successes,
she challenged the field to thoughtfully consider which
type of astrocyte each protocol in fact yields and the rele-
vance of these astrocytes to those occurring in vivo. Ebert
closed by discussing recent findings from hiPSC astrocyte
studies regarding the cell non-autonomous effects underly-
ing reduced synaptic puncti in spinal muscular atrophy
(SMA) hiPSC-derived motor neurons (Ebert et al., 2009;
Sareen et al., 2012). SMA is a genetic childhood disease
characterized by motor neuron loss that is believed to
be due to a reduction in the amount of survival motor
neuron (SMN) protein in motor neurons. She reported
that astrocyte activation could be a non-cell-autonomous
contributor to disease, as when SMN is reduced in hiPSC as-
trocytes and there is increased astrocyte reactivity, and that
co-culture of neurons with SMA astrocytes leads to
neuronal phenotype. Together, this work begins to answer
why motor neurons are uniquely vulnerable in SMA when
SMN is a ubiquitously expressed protein, as it may be that
increased astrocyte reactivity ultimately leads to the
reduced synaptic puncti observed in SMA hiPSC motor
neurons.
Pierre Vanderhaeghen, from the University of Brussels,
described efforts to generate defined cortical circuits from
hiPSCs (Espuny-Camacho et al., 2013). Their differentia-
tionmethods seemed to closelymirror embryonic develop-
ment, as hiPSCs differentiated first to cortical progenitors,
then to pioneer neurons, then to deep layer pyramidal
neurons, and finally to upper-layer pyramidal neurons.
Although the human timeline was drastically extended,
this same pattern was observed in both mouse (1-week)
and human (3-month) cells (Nagashima et al., 2014). Using
a 3D default differentiation protocol in Matrigel (3DDM
differentiation), which yields spheres for analysis within
21 days, Vanderhaegen’s group analyzed lines from sub-
jects with autosomal recessive primary microcephaly
(mutations in the ASPM gene) (also termed microcephaly
primary hereditary [MCPH]). Just as ASPM mutations
disrupt corticogenesis in the earliest stages, he reported
increased neuronal differentiation, although with reduced
cortical marker expression, as well as mitotic spindle devi-
ations, in the mutant cells compared to controls. Such
phenotypes were not detected in ASPM mutant mice,
which display only mild microcephaly, suggesting that
ASPM mechanisms of action may be in part species-spe-
cific, underscoring the importance of studying human
health in human cells. Moreover, this impairment was
not due to the hypothesized defect in proliferation but
was more likely the result of perturbed cellular patterning,
which could be corrected by applying WNT inhibitor;
hence, these models can truly generate novel unexpected
mechanistic insights. Finally, Vanderhaegen reported that
PSC-derived cortical cells can be transplanted in neonatal
mice, where human neurons develop normally but mature
at a considerably slower pace than their mouse counter-
parts (over 9 months instead of 4 weeks), reminiscent of
the neoteny that characterizes neuronal maturation in
human cortex.
Madeline Lancaster, from the Institute of Molecular
Biotechnology (IMBA) and the MRC Laboratory of Mo-
lecular Biology, discussed using cerebral organoids to
examine pathogenesis of neurodevelopmental disorders
(Lancaster et al., 2013). She noted the many advantages
of these self-organizing 3D mixed cultures of human cells,
including organized progenitor zones and sequential
generation of neuronal layer identities. These organoids
comprise radial glia progenitor cells and neurons with
good cortical pyramidal morphology. Nonetheless, these
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mixed cultures lack axis patterning, show high variability
(line to line and batch to batch), and show a loss of neu-
rons with extended differentiation. At their current state
of development, organoid assays are likely ideal for study-
ing disorders of neurodevelopment (particularly microen-
cephaly), neurogenesis, and fate specification. Noting that
microencephaly is not adequately modeled in rodents,
Lancaster, in work performed in the lab of Juergen Kno-
blich, generated hiPSCs from a microencephaly patient
with a null mutation in centrosomal protein CDK5RAP2
(independent mutations at either allele). She observed a
depleted progenitor population and premature neuronal
differentiation, demonstrating the precision of this plat-
form in resolving microencephalic phenotypes.
Using a similar strategy, Flora Vaccarino, from Yale
University, described applying telencephalic organoids to
model early developmental trajectories in autism spectrum
disorders (ASD). She noted that human-based studies are
critical, owing to fundamental differences in cortical devel-
opment and timing between humans and mice. Concerns
with hiPSCs remain, of course, particularly concerning the
potential genetic instability of hiPSCs, which show an
accumulation of mutations, tracing back in large part to
the original fibroblast population: 30% of skin fibroblasts
carry one to two large somatic copy number variants
(CNVs), and there is wide variability in the frequency of
different mosaic mutations among fibroblast cells (15%–
0.3%) (Abyzov et al., 2012). Nonetheless, by applying a
neuronal differentiation strategy based upon 3D cortical
organoids, Vaccarino demonstrated patient-specific molec-
ular and cellular phenotypes in ASD hiPSC-derived neu-
rons. She reported a methodology for generating cortical
organoids that are more homogeneous in structure,
composed of repeating units of rosettes, and for which
RNA sequencing comparison to the BrainSpan dataset
revealed closest similarity to early fetal brain tissue. She
cautioned that specific transcriptome differences exist
between isogenic intact organoids and dissociated progen-
itors. Noting that an increase in brain and head size (i.e.,
macrocephaly) characterizes a subset of ASD patients
with poorer outcome, Vaccarino described a study where
organoids from patients were systematically compared to
those from their fathers in transcriptomics and cellular
phenotypes. She reported that ASD hiPSC-derived organo-
ids show a complex cellular phenotype that includes
decreased cell cycle length, upregulation of genes directing
gamma-amino butyric acid (GABA) neuron fate, increased
synaptogenesis and dendrite outgrowth, and changes
in synaptic activity. Global gene co-expression network
analysis of cortical organoids resolved a number of gene
modules that were differentially expressed in ASD individ-
uals, including one potentially driven by FOXG1, a master
regulatory transcription factor that was greatly upregulated
in ASD. Interestingly, knockdown of FOXG1 in ASD-
derived iPSCs normalized the shift in GABA phenotype
in ASD cortical organoids, suggesting a potential causal
pathway in the ASDGABAergic imbalance phenotype (Ma-
riani et al., 2015).
Dimensions of Modeling
As the disease modeling field is developing both more reli-
able in vitro protocols for neural differentiation and more
accurate phenotypical functional readouts, researchers
are beginning to explore neurological diseases that have
more complex etiologies. While highly penetrant mono-
genic disorders such as Rett and Fragile X syndromes
remain among the most tractable areas for iPSC research,
the majority of CNS diseases are multigenic, have incom-
plete penetrance, and are subject to significant environ-
mental influences. One way to circumvent the variability
in phenotypes is to stratify the population of patients.
Selecting for specific clinical cohorts such as biologically
relevant measures, i.e., the brain size phenotype, drug
responsiveness, endophenotypes, or specific genetic co-
horts containing specific genetic variations with clinical
relevance, can provide valuable information toward pa-
tient-tailored biomarkers and therapies.
Carol Marchetto, from the Salk Institute of Biological
Studies, extended her previous characterization of a mono-
genic form of ASD (Rett syndrome) (Marchetto et al., 2010)
by recruiting a genetically heterogeneous cohort of
patients with ASD, characterized by an endophenotype of
transient macrocephaly, and comparing them to gender-
and age-matched unrelated controls. ASD-derived neural
progenitor cells (NPCs) display increased cell proliferation
due to a dysregulation of a b-catenin/BRN2 transcriptional
cascade, while ASD-derived neurons displayed premature
differentiation, reduced synaptogenesis, and altered levels
of excitatory and inhibitory neurotransmitters, leading to
functional defects in neuronal networks, measured by
multielectrode arrays. Interestingly, RNA analysis also
revealed increased expression of FOXG1 in ASD NPCs, in
agreement with Flora Vaccarino’s data in a completely in-
dependent set of experiments, suggesting that there may
be common features in macrocephalic ASD and pointing
to a potential target of therapeutic intervention.
Kristen Brennand, from the Icahn School of Medicine at
Mount Sinai, spoke about the inherent value of modeling
predisposition, rather than end-stage disease, in the
context of schizophrenia (SZ), noting that gene expression
patterns characteristic of SZ hiPSC neurons (Brennand
et al., 2011) are conserved in SZ-hiPSC-derived NPCs (Bren-
nand et al., 2015). She presented several phenotypical read-
outs that would be predictive for SZ predisposition in vitro,
such as migration defects (Brennand et al., 2015), WNT
signaling defects (Topol et al., 2015), and perturbations in
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neuronal connectivity (Brennand et al., 2011) and activity
(Yu et al., 2014). By studying the disease phenotype
in vitro, she also gained some insight on the disease
biology; through the analysis of global expression profiles
from SZ-derived NPCs, she reported differential expression
of genes and microRNAs related to the migration changes
observed in vitro. Additionally, Brennand is working with
patient families and a cohort of childhood-onset SZ pa-
tients to correlate SZ-related genetic mutations with gene
expression levels.
Given the vast clinical heterogeneity of major mental
illness, Akira Sawa, from John Hopkins University School
of Medicine, advocated careful patient stratification when
selecting cohorts for hiPSC-based disease modeling. He
argued that traditional Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) (American Psychiatric Associa-
tion, 1994) diagnosis does not provide enough neurobio-
logically relevant information for patient recruitment for
basic research and proposed that other criteria such as clin-
ical longitudinal assessment, neuropsychology examina-
tion, brain imaging, and correlation between intermediate
phenotypes and disease-related genetic polymorphisms
should be considered. By screening olfactory NPCs ob-
tained from a larger clinical cohort of patients with
SZ and bipolar disorder (BD) with psychotic features, he
identified those patients with reduced phosphorylation
(pS713) of disrupted in schizophrenia 1 (DISC1), indepen-
dent of clozapine treatment, and selected them for further
hiPSC-based characterizations. Reduced (pS713) DISC1
phosphorylation was replicated in hiPSC neurons, and
levels of p713-DISC1 correlated to neuropsychological
and anatomical changes, highlighting the importance of
patient stratification in complex neuropsychiatric diseases.
He proposed that such clinical phenotype-based stratifica-
tion of the subjects for hiPSC research could also be applied
for unique subsets of SZ and mood disorders, such as psy-
chotic depression and rapid-cycling BD.
Hongjun Song, from Johns Hopkins University School of
Medicine, generated hiPSC-derived cortical neurons from
four members of a SZ family pedigree defined by a deletion
mutation ofDISC1 gene (4-base-pair frameshift deletion on
exon 12) (Chiang et al., 2011), observing decreased excit-
atory postsynaptic current (EPSC) frequencies and synaptic
vesicle protein 2 (SV2) puncta density in patients with the
mutation, which were rescued by both transcription acti-
vator-like effector nucleases (TALEN)-mediated genetic
correction (Wen et al., 2014). Subsequent RNA sequencing
showed DISC1-associated changes in expression of genes
involved in neuronal development, synaptic transmission,
and those related to mental disorders. Complementary
data obtained from genetically modified mice with this
same DISC1 mutation highlighted the continued value
of mouse models to study the role of specific mutations
independent of genetic background, as a means of cross-
paradigm validation of results obtained with hiPSCs, at
the levels of neuronal circuits and behavior, and for in vivo
drug testing.
Eric Morrow, from Brown University, showed data from
patients with a recently described condition termed Chris-
tianson syndrome (CS), a monogenetic X-linked disorder
caused by mutations in the endosomal sodium/hydrogen
exchanger 6 protein (NHE6) (Pescosolido et al., 2014). His
laboratory has engineered iPSCs from peripheral blood
mononuclear cells from patients with CS and their unaf-
fected male siblings. His studies are investigating a variety
of endosomal phenotypes in iPSC-derived neurons as
well as cellular phenotypes related to abnormal neuronal
differentiation. They are using these cellular assays as plat-
forms to screen candidate treatments. His study empha-
sized several themes, including pursuing various paths to
assemble control cells as well as using statistical methods
on experiments on multiple mutations with different sub-
clonal lines. Further, Morrow’s studies capitalize on his
access to patient clinical assessments, a mouse model, as
well as iPSCs. Combining these in vivo studies with the
in vitro iPSC studies may prove to be a powerful approach.
Frank Soldner, from theWhitehead Institute for Biomed-
ical Research, having previously generated isogenic hiPSCs
at two-point mutations in early-onset Parkinson’s disease
(PD) (Soldner et al., 2011), now presented studies on the
penetrance of non-coding PD risk alleles. Meta-analysis of
genome-wide association study (GWAS) data from 13,708
PD cases has identified 26 significant PD-associated loci;
however, there is a lack of mechanistic insight in how
such sequence variants functionally contribute to complex
disease. Soldner proposed that functional disruption of
distal enhancer elements leads to the deregulation of
gene expression and confers susceptibility to PD. As a proof
of principle to study the consequence of these mutations
on gene expression, he conducted functional analysis of
cis-regulatory elements in the SNCA locus via genome edit-
ing tools in order to precisely disrupt regulatory elements
in isogenic pairs. He used quantitative allele-specific assays
as readouts and showed that common single nucleotide
polymorphisms (SNPs)with small effect size can contribute
to PD risk. This work highlights the importance of corre-
lating previously identified disease-related mutations
(SNPs and CNVs) with changes in expression profile
in vitro in order to identify functional disease-relevant
risk variants and determine the mutation’s impact.
Rick Livesey, from the Gurdon Institute, provided
insights into mechanisms of Alzheimer’s disease (AD)
pathogenesis using human stem cell models (Shi et al.,
2012). The cellular hallmarks of AD are the accumula-
tion of amyloid precursor protein (APP) protein-derived
Ab peptide fragments and neurofibrillary tangles of the
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microtubule-associated protein tau. Livesey described the
characterization of hiPSC neurons derived from patients
with different familial AD mutations in the APP gene or
Presenilin1 (PSEN1), the enzymatic subunit of the g-secre-
tase complex that processes APP. All of the different muta-
tions increased the release of pathogenic longer forms of
Ab peptides. However, while increased APP gene dosage
and APP mutations all increased total and phosphorylated
tau in neurons, PSEN1 mutations did not (Moore et al.,
2015). Manipulating g-secretase activity in human neu-
rons, using available drugs, identified that APP processing
is linked to regulating levels of tau protein, hinting that
extracellular Ab may not be the only process relevant to
disease pathogenesis. His work proposes a cell-autono-
mous link between APP processing and tau.
Lorenz Studer, from Memorial Sloan-Kettering Cancer
Center, described work modeling two rare human diseases,
familial dysautonomia (FD) and Hirschsprung’s disease
(colonic aganglionosis). FD is a rare recessive disorder,
occurring when a T/ C point mutation leads to skipping
of exon 20 in iKBKAP/ELP1. Deriving hiPSCs from patients
with both severe (S1 and S2) and mild (M1 and M2) FD, he
found that patient-derived hiPSC neurons clearly modeled
clinical outcome; relative to unaffected controls, severe FD
patients had difficulty generating BRN3A sensory neurons,
whereas mild FD patients did not (sensory neurons from
both classes of patients die within 28 days). To study
Hirschsprung’s disease, a fatal if untreated disease in which
there is incomplete migration of the enteric nervous
system, Studer described a differentiation protocol that
successfully generates vagal and enteric neural crest from
hESCs that express appropriate cell-type-specific BRN3A/
ISL1 markers, produce slow wave activity in vitro, and
properly innervate the colon when transplanted into
mice (Chambers et al., 2013). hESC-derived ENRB/ and
RET/ enteric neural crest cells showed reducedmigration
in vitro and in vivo. A high-throughput screening (HTS)
assay for compounds that rescue these migration deficits
identified Pepstatin A. Studer concluded by discussing the
technical challenges in studying disorders that require
cell types that require significant maturation and aging,
some of which are potentially addressable through overex-
pression of progerin (Miller et al., 2013), as well as methods
and assays under-development to address these challenges.
For example, he described combining a method to rapidly
differentiate cortical neuronswith in vivo cell engraftment,
in collaboration with Marc Tessier-Lavigne, to yield sub-
stantial morphological integration of neurons when
imaged by iDISCO, a novel 3D immunohistological pro-
cessing and imaging technique (Renier et al., 2014); this
strategy will allow mapping of the connectivity of human
neurons derived from patients with a variety of neurodeve-
lopmental disorders.
Sally Temple, from the Neural Stem Cell Institute, has
applied a robust hiPSC differentiation protocol to retinal
pigment epithelium (RPE) to understand molecular mech-
anisms underlying age-related macular degeneration
(AMD) (Stanzel et al., 2014), a highly prevalent neurode-
generative disease affecting one in five people older than
age 75. A characteristic sign of the early, dry form of AMD
is the appearance of large extracellular deposits termed
drusen in the macula. Proteomic analysis has demon-
strated that drusen share many molecular characteristics
with senile plaques in AD. Observing significantly higher
expression of AMD and drusen-associated transcripts,
particularly Ab42 and Ab40, in AMD iPSC-RPE than in
controls, the group took a candidate-based approach and
identified several small molecules that reduce AMD-associ-
ated transcripts in iPSC-RPE, in some cases irrespective of
original AMD disease status. These findings suggest that
this in vitro model may be valuable to identify dry AMD
therapeutics.
In aggregate, it has become obvious that by more accu-
ratelymodeling humanneurodevelopmental and neurode-
generative diseases in vitro, a number of insights into the
cellular and molecular mechanisms underlying the disease
state have already arisen. hiPSC-based platforms, com-
bined with genome-scale analyses of sequence variations
and transcripts, are increasingly facilitating studies of
the temporal dynamics of human disease and allowing
researchers to study human-specific elements of disease,
asking when critical changes occur in the disease process.
From insights into the mechanisms of tau changes in AD,
to increased FOXG1 expression in two hiPSC cohorts of
ASD, to the critical role of ASPN inmicroencephaly, cellular
models are revealing convergent mechanisms underlying
genetically heterogeneous neurological conditions.
Somatic Mosaicism
An emerging issue in the stem cell field is somatic mosai-
cism, the presence of DNA structural and/or sequence
variation from cell to cell in a given individual. This raises
interesting questions about not only the role of this form of
cellular heterogeneity in health and disease but also the
utility of any single patient-derived iPSC line in accurately
representing that patient’s disease state. Alysson Muotri,
from University of California, San Diego, presented data
on iPSC-derived neurons from patients with Aicardi-Gou-
tieres syndrome (AGS), a neurodevelopmental disease
characterized by intellectual and physical problems with
neuroinflammation.Muotri made iPSCs fromAGS patients
with mutations on TREX1 gene related to clearance of
L1 mobile elements from the cytosol and compared them
with isogenic controls. TREX1-mutant cells have high
levels of single-stranded DNA (ssDNA) derived from mo-
bile retroelements (Alus and L1s) in the cytoplasm and
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decreased expression of neuronal markers TLG4, MAP2,
TUJ1, and SYN. These features were partially rescued by
treatment with reverse transcriptase inhibitors (such as
anti-HIV drugs), indicating clinical relevance on this
extreme neurological condition. Additionally, TREX1-defi-
cient astrocytes also increased ssDNA and triggered an in-
flammatory response that affected neurons, suggesting a
non-cell-autonomous inflammatory effect that may be
contributing to neuronal loss in AGS. The TREX1mutation
highlights the importance of human models, since mouse
models for the disease don’t present any neurological
symptoms.
Mike McConnell, from University of Virginia School of
Medicine, presented the use of hiPSC-based neurogenesis
to study brain mosaicism (McConnell et al., 2013). His
strategy is to perform single cell genomic sequencing. His
data from primary brain showed that 45/110 human fron-
tal cortex neurons had megabase-scale CNVs. Similarly, he
detected similar levels of mosaic CNVs in hiPSC-derived
neurons but very low levels of mosaicism in hiPSC-derived
NPCs or human fibroblasts. These data suggest that some
aspects of primary brain somatic mosaicism are recapitu-
lated during hiPSC-based neurogenesis. His laboratory
is currently defining the levels of genetic mosaicism in
neuronal cultures to understand the impact of mosaicism
on disease modeling. New data were presented using
hiPSC-based neurogenesis to investigate the cause and
consequence of brain somatic mosaicism.
It is increasingly clear that somatic mosaicism occurs in
both post-mortem and hiPSC neurons. What remains to
be determined is the precise extent of this phenomenon
in the human brain, its mechanisms, and the precise role
that mosaicism contributes to evolution, human behavior
and disease, and even the ‘‘normal’’ physiological condi-
tion. Moving forward, future hiPSC experiments should
be designed with a consideration of the existence of so-
matic mosaicism, incorporating (1) analysis of multiple
iPSC lines per patient, (2) isogenic engineering, and (3)
phenotypic rescue experiments.
Using hiPSCs for Drug Discovery
Amajor goal in the still nascent human stem cell field is to
utilize improved cell-based assays in the service of small-
molecule therapeutics discovery and virtual early-phase
clinical trials. Ajamete Kaykas, from the Novartis Institute
for BioMedical Research, discussed the pharmaceutical
pipeline to identify phenotypes in human pluripotent
stem cell (hPSC)-derived neurons. He demonstrated that
in a non-academic setting, it is possible to establish a library
of more than 100 transgene-free hiPSCs as well as a
clustered regularly interspaced short palindromic re-
peats (CRISPR) pipeline to create and screen clones for
indels, knockout, and point mutation via high-throughput
sequencing methods. In parallel, his group has tested the
feasibility of scaling both directed differentiation as well
as NGN2-induction protocols into 384-well plate format
for high-throughput screening. Overall, both a robust
hPSC pipeline for hiPSC-based modeling as well as stan-
dardized and automated differentiation methods are being
established at Novartis, in collaboration with the Stanley
Center, for the characterization and drug screening of SZ
patients.
Lee Rubin, from Harvard University, discussed the chal-
lenges and successes his laboratory has encountered, in
the academic setting, while establishing hiPSC-based
high-throughput drug screening for SMA. Given that there
are three types of SMA, fatal within the first year of life
(type 1), by the teenage years (type 2), and characterized
by chronic immobility (type 3), Lee asked whether SMA is
in fact one disease or three. To determine why motor
neurons from some SMA patients are more sensitive than
others, he generated hiPSCs from patients with all three
types of SMA, observing that SMA iPSCs have an increased
propensity to generate NPCs and a slightly decreased
propensity to yield endoderm, consistent with clinical
observations that children with SMA have other defects,
particularly in endodermal and cardiac tissues. Compared
to controls, SMA motor neurons show increased cell
death, apoptotic station, reduced neuronal outgrowth,
and decreased neuronal firing (SMA3 > SMA2 > SMA1),
and regardless of diagnosis, non-motor neurons do not
die. Lee conducted three high-throughput screens for com-
pounds to prevent cell death in SMA (ES-derived motor
neurons from SMN-deficient mice, SMA patient fibro-
blasts, and SMA hiPSC-derived motor neurons). Unbiased
screens in mouse motor neurons, human motor neurons,
and human fibroblasts identified many compounds that
increased SMN levels, only some of which overlapped
between platforms: while some compounds that block
SMN degradation were hits in all three screens, proteasome
inhibitors were found in the fibroblast screen but proved
toxic tomotor neurons (MNs). On the basis of high content
imaging data generated through the various screens, his
group also observed that at the level of single cells, whether
from control or SMA hiPSCs, there is cell-to-cell variation
in SMN levels; individual cells with high SMN are the fittest
and survive better than neighboring cells with lower SMN,
implying that SMN is a general regulator of motor neuron
survival, likely owing to reducing activation of the endo-
plasmic reticulum (ER) stress response. Moreover, inhibi-
tors of the degradation process do not promote survival
of SMN neurons below a defined basal level but shift the
distribution of SMN, producing more neurons with levels
that support survival. On the other hand, compounds
that reduce ER stress don’t affect SMN levels at all but still
promotemotor neuron survival. Lee summarized problems
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that arise in high-throughput screening of hiPSC-derived
cells as those arising due to issues of neuronal variability,
immaturity, and non-cell-autonomous disease-relevant
interactions.
In discussions among attendees, it became apparent that
pharmaceutical and academic scientists approach drug
discovery with different perspectives. Traditionally, most
academics seek to test the cell typemost relevant to disease,
pursuing a candidate-based approach to test effects on
phenotypes, whereas industry scientists have historically
conducted high-throughput screens on entrenched indus-
try-standard screening cell lines using target-based assays.
While academics have typically been willing to develop
more ‘‘risky’’ assays, the strengths of pharma have histori-
cally been in assay selection, scalability, and optimization,
as well as drug chemistry and target optimization. Now,
research strategies are converging, and both types of re-
searchers are moving toward hiPSC-based screening
platforms, drifting toward a hybrid model of testing me-
dium-throughput libraries, screening 30,000 compound
libraries with known targets. New collaborations between
academic and pharma researchers promise a future of paral-
lel screening for both targets and phenotypes. Additional
hurdles will be encountered if academics are to be the
new drivers of drug discovery, including replication (across
platforms/reproducibility across sites), documentation (to
the rigor of record keeping in industry), and investments
to increase automation.
Perspectives and Summary
In line withmany of these themes, David Panchision, from
the National Institute of Mental Health (NIMH), discussed
recent funding initiatives to facilitate cell-based research
on mental illness, including those supporting technol-
ogy development and academic-industry partnerships for
developing validated assays. He solicited feedback on
NIMH priorities for advancing the field, which involve in-
vestigators working together to: (1) implement centralized
sharing of patient and reference cell lines with genetic
and clinical data, such as through the NIMH Repository
and Genomics Resource (https://www.nimhgenetics.org/);
(2) arrive at common cell-line quality control methods
and standards for validating hiPSCs and differentiated
cell types; (3) keep improving hiPSC-based technology,
including developing easier andquicker targetingmethods,
optimizing the fidelity of ‘‘in vivo’’ surrogate assays like chi-
meras andorganoids, improving assayminiaturization, and
scaling up to increase thenumber of individualswho canbe
contrasted by these strategies; (4) focus on robustness and
reproducibility, which can include studying genetic vari-
ants of large effect from fully characterized patients and
maintaining consistency and transparency in protocols/
samples across labs; and (5) remain mindful of the critical
value of collaboration and training and supporting the
rapid dissemination of best practices (Panchision, 2013).
There was agreement that, although it was important to
maximize the rapid sharing and adoption of resources/
methods for patient-based disease studies, it was critical
that this be balanced with the need for innovation at this
early stage in the field. For example, although reprogram-
ming technologies had advanced tremendously, some par-
ticipants cautioned funding organizations to not restrict
iPSC production to a singlemethod or provider, since ques-
tions still remained about best practices. Additionally,
analysis of specific biological processes or disorders may
benefit from tailored cell derivation technologies (e.g.,
parthenogenesis), stem cell patterning (e.g., naive versus
primed hiPSCs), and strategies for genetic manipulation
(e.g., CRISPR-Cas9 versus TALEN).
The meeting highlighted the diverse array of cell-based
approaches that are being pursued to study human biology
and disease, including those (e.g., somatic mosaicism) that
illustrated the possibilities and potential limitations of
these technologies. Our group was heartened that we are
seeing clear disease-related phenotypes in the dish, giving
some confidence that discoveries (such as those reflecting
early stages in disease processes) would be clinically rele-
vant. Moreover, as such discoveries are being made, unex-
pected findings are emerging, but the convergence and
reproduction among labs improve our group’s optimism
that these are robust results and that human cells will
be a powerful tool in the therapeutic development arma-
ment. Moving forward, a critical application of hiPSC-
based studies will be in providing a platform for defining
the cellular, molecular, and genetic mechanisms of disease
risk, which will be an essential first step toward target
discovery. Toward this goal, the case studies discussed
demonstrated that different assay systems could yield a
surprising convergence of phenotypes, leading to some
optimism that the considerable remaining technical chal-
lenges to modeling disease are still surmountable.
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